XOMA appoints Paul Rubin vice-president and CMO
This article was originally published in Scrip
XOMA, a company focused on the discovery and development of novel antibody therapeutics, has appointed Dr Paul Rubin vice-president and chief medical officer. Dr Rubin was previously CMO at Funxional Therapeutics. He will succeed Dr Patrick Scannon, who has been executive vice-president and CMO since 2009 and will now serve as executive vice-president and chief scientific officer.